降糖治疗对2型糖尿病人sE-选择素水平影响研究

The effects of glycaemic control on plasma soluble E-selectin levels in patients with type 2 diabetes mellitus

目的研究降糖治疗对2型糖尿病患者血浆可溶性E-选择素的影响。方法应用酶联免疫吸附法检测60例2型糖尿病患者降糖治疗前后血浆sE-选择素水平,并与23例正常对照组比较。结果治疗前糖尿病患者sE-选择素水平明显高于对照组。sE-选择素水平与HbA1c、果糖胺、BMI、空腹C肽正相关。治疗3周后sE-选择素水平明显下降,但仍未降到对照组水平。结论 sE-选择素与肥胖、高血糖相关。2型糖尿病患者降糖治疗可通过降低血中sE-选择素水平,从而有助于防止和改善血管并发症的发生和发展。

Objective To investigate the effects of glycaemic control on plasma soluble E - selectin （sE - se- lectin） levels in patients with type 2 diabetes mellitus. Methods The enzyme- linked immunosorbent assay was used to measure the plasma sE - selectin before and after glycaemic control in 60 patients with type 2 diabetes melli- tus, and compared with 23 healthy subjects （control group）. Results Before treatment, sE - selectin levels were significantly higher in diabetic patients than in nondiabetic control subjects, sE - selectin concentrations were posi- tively correlated with body mass index （BMI）, HbA1C, fructosamine and fasting C - peptide. 3 weeks after gly- cacemic control treatment, sE- selectin decreased significantly, but these levels still didn＇t reach to those of control subjects. Conclusion Plasma sE - selectin levels may be related to obesity, hyperglycemia. Down- regulation plasma sE- selectin in glycaemic control for patients with type 2 diabetes mellitus might be contributed to prevent and treat diabetic vascular complications.